Organization and Nature of Business (Tables)
|
3 Months Ended |
Mar. 31, 2025 |
|---|
| Organization and Nature of Business [Abstract] |
|
| Schedule of Details of Shareholders |
Details
of shareholders as of March 31, 2025 are as follows:
| Name of Shareholder | |
Number of
ordinary share | | |
Percentage of
ownership | |
| Bellevue Global Life Sciences Investors LLC | |
| 1,332,500 | | |
| 6.91 | % |
| Bellevue Capital Management Europe AG | |
| 8,612,634 | | |
| 44.68 | % |
| Bellevue Capital Management LLC | |
| 3,123,970 | | |
| 16.21 | % |
| Duksung Co.,Ltd. | |
| 1,420,215 | | |
| 7.37 | % |
| Others | |
| 4,787,659 | | |
| 25.68 | % |
| Total | |
| 19,276,978 | | |
| 100.00 | % |
|
| Schedule of Investments in Subsidiaries |
Details
of investments in subsidiaries as of March 31, 2025 are as follows:
| Name of subsidiary | | Share capital | | | Percentage of ownership | | | Principal activities | | Country of
incorporation | | VAXIMM AG (“VAXIMM”) | | | 1,091,203,754 | | | | 100.00 | % | | Biotech (drug development) | | Switzerland | | RMC Co., Ltd. (“RMC”) | | | 35,000,000 | | | | 100.00 | % | | Medical device distribution | | Republic of Korea | | Darnatein Co., Ltd. (“Darnatein”) | | | 6,466,667,000 | | | | 100.00 | % | | Biotech (drug development) | | Republic of Korea | | OSR Holdings, Inc. | | | 2,826,969 | | | | 100.00 | % | | SPAC | | The United States |
|
| Schedule of Key Financial Information |
Key financial information of the subsidiaries
at March 31, 2025 are as follows :
| Name of subsidiary | |
Asset | | |
Liability | | |
Equity | | |
Sales | | |
Net Income
(loss) | |
| VAXIMM AG | |
$ | 910,415 | | |
$ | 386,254 | | |
$ | 524,161 | | |
$ | - | | |
$ | (78,609 | ) |
| RMC Co.,Ltd | |
| 2,040,181 | | |
| 1,568,695 | | |
| 471,486 | | |
| 761,272 | | |
| (211,541 | ) |
| Darnatein Co.,Ltd | |
| 110,171 | | |
| 678,651 | | |
| (568,481 | ) | |
| - | | |
| (141,742 | ) |
| OSR Holdings, Inc. | |
| 1,687,119 | | |
| 10,071,814 | | |
| (8,384,695 | ) | |
| - | | |
| - | |
|
| Schedule of Summaries of Entities |
Summaries
of entities, which are newly included in consolidation scope for the periods ended March 31, 2025 and 2024 are as follows:
| For the year ended March 31, 2025 | | Name of subsidiary | | Reason | | Type of purchase consideration | | OSR Holdings, Inc. | | Acquisition (*1) | | Equity swap with shares of the Parent and OSR inc.’s share |
|